Items tagged with Access
India’s focus on coronavirus leaves TB and HIV patients adrift (post)
The lockdown imposed to contain Covid-19 has made it difficult for people with other diseases to access the medicines they need to survive.
Coronavirus lockdown complicates Philippines's fight against TB (post)
Campaign to end TB in the country sidelined as healthcare workers fight to contain spread of pandemic.
If J&J really wants to support nurses, it should make the TB drug bedaquiline affordable (post)
As nurses who worked in 5B, the first U.S. hospital ward dedicated HIV/AIDS, which opened in San Francisco General Hospital in 1983, we have been directly affected in profound ways by the disease and its opportunistic infections.
Global TB community must unite – 1.4 million lives are at stake (post)
The Stop TB partnership predicts an additional 1.4 million people will die from TB by 2025 thanks to the COVID-19 response.
Increased access to pretomanid/BPaL regimen (post)
27 May 2020, Geneva, Switzerland – On 28 October 2019, the Stop TB Partnership announced the addition of pretomanid to the Global Drug Facility (GDF) catalog as part of a BPaL regimen containing bedaquiline, pretomanid, and linezolid. GDF supplies pretomanid to countries in accordance with WHO recommendations for people with extensively drug-resistant TB (XDR-TB) when used under operational research conditions.
Deltyba® (delamanid) approved in the Russian Federation for the treatment of pulmonary MDR-TB (post)
-- Deltyba® (delamanid) — an essential medicine according to the World Health Organization [1] — is now available in Russia for difficult-to-treat MDR-TB patients.
-- Deltyba® (delamanid), developed by Otsuka Pharmaceutical Co., Ltd. based in Japan, is commercialized in Russia by the R-Pharm group of companies.
U.S. FDA approves new pediatric formulation of SIRTURO® (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant TB (post)
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided.
Following US FDA approval, child-friendly bedaquiline available from Stop TB Partnership's GDF Pediatric DR-TB Initiative (post)
11 June 2020, Geneva, Switzerland– The Stop TB Partnership’s Global Drug Facility (GDF) today announced the addition of child-friendly bedaquiline 20 mg tablets to the GDF Pediatric DR-TB Initiative. The US FDA approval of the medicine, on 27 May 2020, marks a new milestone for all-oral DR-TB regimens in children who are older than 5 years of age and weighing more than 15 kilograms. These children will now benefit from the same optimized treatments being provided to their parents – no more injections for anyone.
High price excludes patients from better treatment for drug-resistant TB (post)
NAIROBI — Sheila Baraza, a 30-year-old resident of Ruaka, a city to the northwest of Nairobi, unsuccessfully fought back tears as she recalled the pain of seeking and then undertaking a two-year treatment for drug-resistant tuberculosis.
COVID-19: Proposals for achieving equitable global access for treatments, vaccines and diagnostics (post)
The Access to COVID-19 Tools Accelerator (ACT-A) was launched by the World Health Organization (WHO), governments and global health actors as an ‘unprecedented and inclusive partnership’ to address some of the challenges linked with the management of the COVID-19 emergency and the development and delivery of needed treatments, vaccines and diagnostics.
Page 42 of 83 · Total posts: 0
←First 41 42 43 Last→